ZELVYSIA (sapropterin dihydrochloride) (Sapropterin Dihydrochloride POWDER, FOR SOLUTION) 500 mg/1

ZELVYSIA (sapropterin dihydrochloride) is an oral medication approved by the FDA as an orphan drug for the treatment of phenylketonuria (PKU), a rare inherited metabolic disorder. It belongs to the endocrinology and metabolic disorder therapeutic category and represents an important treatment option for patients with tetrahydrobiopterin (BH4)-responsive PKU.

Strength

500 mg/1

Pack Size

30 PACKET in 1 CARTON (73289-0071-2) / 1 POWDER, FOR SOLUTION in 1 PACKET (73289-0071-1)

Manufacturer / TM Owner

Aucta Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ZELVYSIA is indicated for the treatment of phenylketonuria (PKU) in patients with tetrahydrobiopterin (BH4)-responsive disease. PKU is a rare autosomal recessive metabolic disorder characterized by deficiency of the enzyme phenylalanine hydroxylase, leading to elevated blood phenylalanine levels that can cause severe neurological damage, intellectual disability, and developmental delays if untreated. ZELVYSIA works as a synthetic form of BH4, a natural cofactor that enhances residual phenylalanine hydroxylase activity in responsive patients. The drug is designed for pediatric and adult patients diagnosed with BH4-responsive PKU who have demonstrated responsiveness to sapropterin therapy. By reducing blood phenylalanine concentrations to therapeutic levels, ZELVYSIA helps prevent or minimize neurological complications associated with PKU, improving long-term health outcomes and quality of life. Treatment typically requires concurrent dietary protein restriction and regular monitoring of blood phenylalanine levels.

Side Effects

Common side effects of ZELVYSIA include headache, rhinitis, pharyngitis, diarrhea, vomiting, and abdominal pain. Serious adverse events, though rare, may include hypersensitivity reactions and convulsions. Patients may experience gastrointestinal disturbances, fever, and rash. Regular monitoring of blood phenylalanine levels is essential to assess therapeutic efficacy and guide dosage adjustments. Baseline and periodic evaluation of renal function and blood pressure is recommended. Patients should be monitored for signs of hypersensitivity reactions during treatment initiation. Compliance with dietary management and regular laboratory assessments are critical components of comprehensive PKU management.

Precautions & Warnings

ZELVYSIA is contraindicated in patients with known hypersensitivity to sapropterin or any excipients. Caution is advised in patients with renal impairment or hepatic dysfunction, as dose adjustments may be necessary. Safety in pregnancy has not been established; however, untreated PKU poses significant risks to fetal development, requiring careful risk-benefit assessment. Pediatric patients require age-appropriate dosing and close monitoring of phenylalanine levels. Patients with concurrent infections or fever may require temporary dose adjustments. Blood pressure monitoring is recommended, particularly in patients with pre-existing hypertension. Use with caution in patients with cardiac or cerebrovascular disease.

Avoid Interactions

ZELVYSIA may interact with medications affecting nitric oxide metabolism or vascular function. Concurrent use with levodopa should be avoided due to potential competitive inhibition. Phosphodiesterase-5 inhibitors may potentiate hypotensive effects when combined with sapropterin. Patients should inform healthcare providers of all medications, supplements, and herbal products. No significant food-drug interactions have been documented. Regular communication with healthcare providers regarding medication changes is essential to prevent adverse interactions.

Frequently Asked Questions

ZELVYSIA is used to treat phenylketonuria (PKU), a rare inherited metabolic disorder caused by deficiency of the enzyme phenylalanine hydroxylase. It is specifically indicated for patients with tetrahydrobiopterin (BH4)-responsive PKU. By reducing blood phenylalanine levels, ZELVYSIA helps prevent neurological complications and developmental delays associated with untreated PKU.

ZELVYSIA is administered orally as a tablet that is typically dissolved in water or apple juice before consumption. The dosage is individualized based on patient response and blood phenylalanine levels, usually ranging from 5-20 mg/kg/day divided into one to three daily doses. Dosing adjustments are made based on therapeutic response and regular monitoring of phenylalanine concentrations.

Common side effects include headache, rhinitis, pharyngitis, diarrhea, vomiting, and abdominal pain. Most side effects are mild to moderate and manageable. Patients should report persistent or severe symptoms to their healthcare provider for appropriate management and potential dose adjustments.

ZELVYSIA is manufactured by Aucta Pharmaceuticals, Inc., a pharmaceutical company specializing in treatments for rare metabolic and genetic disorders.

Yes, ZELVYSIA received FDA orphan drug designation for the treatment of phenylketonuria. Orphan drug status is granted to medications treating rare diseases affecting fewer than 200,000 people in the United States. This designation provides regulatory incentives and support for the development of treatments for rare conditions like PKU.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.